



ASX Announcement

21 April 2022

Appointment of Ewen Crouch AM as Non-Executive Chairman

The Board of Brisbane headquartered Life Sciences and Energy Technology company, AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") today announced the appointment of Mr Ewen Crouch AM as Non-Executive Director and Chairman-Elect succeeding Dr Jack Hamilton on 30 April 2022.

The appointment of Mr Crouch follows the decision by Dr Jack Hamilton to step down from the role (*refer ASX announcement: 14 March 2022*). Dr Hamilton's retirement from the board will be effective on 30 April 2022.

Mr Crouch is currently Chairman of Corporate Travel Management Limited (ASX: CTD) and serves on the Boards of Bluescope Steel Limited (ASX: BSL) and respected Australian non-profit organisation Jawun.

From 1988-2103 Mr Crouch was a partner at Allens. He served as Chairman of Partners for 4 years and held a number of practice leadership and management roles, including 11 years' service on the firm's board. He was previously a Director of Westpac Banking Corporation Limited (ASX: WBC), a director of Mission Australia including seven years as Chairman, a member of the Takeovers Panel, a member of the Commonwealth Remuneration Tribunal and a director of Sydney Symphony Orchestra.

Mr Crouch's board experience and extensive corporate knowledge, together with his governance, legal and international transaction experience complements well the skillset of the current Board of AnteoTech.

Ewen Crouch commented: *"AnteoTech has a bright future. I'm excited to be joining the Board at such a pivotal time in the Company's history as it seeks to commercialise its technology in the life sciences and energy sectors. I look forward to working with the Board and management team to pursue these opportunities and realise the growth potential in its strategy."*

The Board would like to take this opportunity to thank Dr Jack Hamilton for his commitment to AnteoTech during his tenure as Chairman and wishes him well with his future endeavours.

Subject to shareholder approval to be sought at the next AGM, Mr Crouch will be issued 7m options with an exercise price set at a 50% premium to the 30-day VWAP to 29 April 2022. The options will have a three year term with 50% vesting on 1 May 2023 and the remaining 50% vesting on 1 May 2024. In order to align arrangements for the Board current Non-Executive Directors Dr Katherine Woodthorpe AO and Ms Glenda Mcloughlin will each be awarded 5m options, whilst Geoff Cumming and Christopher Parker will receive an additional 3.5m options each under the same terms as those issued to Mr Crouch, also subject to shareholder approval to be sought at the next AGM.

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.

Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Lates News** bulletin, our email alert service.

